The Phase III CELESTIMO study met its primary progression-free-survival endpoint at an interim analysis, with mosunetuzumab plus lenalidomide producing a statistically significant and company-described clinically meaningful reduction in progression or death versus rituximab plus…
Orbis Medicines and Novo Nordisk entered a multi-target discovery and license collaboration for orally bioavailable synthetic macrocycles against undisclosed cardiometabolic targets. Orbis is eligible for up to $1.4 billion in upfront and development or…
Roche agreed to pay Dualitas Therapeutics $36.5 million upfront for a research collaboration using Dualitas’ DualScreen platform to functionally test more than 300,000 bispecific combinations in immunology and inflammation. Research, development, and commercial milestones…
Innate Pharma and Sobi completed the closing conditions for their lacutamab partnership on September 16. Closing triggers a $75 million payment to Innate and removes the antitrust and other conditions that had kept the…
Remepy appointed Eran Harary, M.D., chief medical officer effective October 1, 2026. He joins from Teva, where he most recently led early clinical development and previously held global specialty R&D and neurology and psychiatry…
Laromestrocel did not improve the primary Month-12 right-ventricular ejection-fraction endpoint in the randomized, 40-infant ELPIS II study of hypoplastic left heart syndrome. The least-squares mean difference was -0.7 percentage points versus surgery alone, with…
Circle Pharma closed an oversubscribed $92.5 million Series E led by The Column Group, with Nextech Invest, RA Capital Management, Euclidean Capital and a strategic investment from Eli Lilly. The company plans to advance…
Sling Therapeutics closed a $123 million Series C led by Forbion, with participation from existing investor TPG Life Sciences Innovations and new investor Sectoral Asset Management. Proceeds will support the 130-participant global Phase III…
FDA cleared IASO208, a CD20-directed in vivo CAR-T candidate built on a replication-incompetent, self-inactivating third-generation lentiviral vector, for U.S. clinical testing in adults with relapsed or refractory B-cell non-Hodgkin lymphoma. IASO Bio expects to…
A Nature paper published online September 16 describes “prime assembly,” a CRISPR-targeted dual-flap synthesis method for RNA-programmable integration of single- or double-stranded DNA without a nuclease-driven double-strand break or cell-cycle dependence. The platform recoded…
